Vitale, A. Et Al. 2022. Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry. FRONTIERS IN MEDICINE , vol.9 .

Vitale, A., Caggiano, V., Maggio, M. C., Lopalco, G., Emmi, G., Sota, J., ... La Torre, F.(2022). Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry. FRONTIERS IN MEDICINE , vol.9.

Vitale, Antonio Et Al. "Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry," FRONTIERS IN MEDICINE , vol.9, 2022

Vitale, Antonio Et Al. "Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry." FRONTIERS IN MEDICINE , vol.9, 2022

Vitale, A. Et Al. (2022) . "Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry." FRONTIERS IN MEDICINE , vol.9.

@article{article, author={Antonio Vitale Et Al. }, title={Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry}, journal={FRONTIERS IN MEDICINE}, year=2022}